100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

View original post here:
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease

– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021

Go here to see the original:
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update

JERSEY CITY, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to potentially overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2020 and provided an update on recent clinical and corporate developments.

Originally posted here:
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update

DOYLESTOWN, Pa., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has changed its official name to Neuropathix, Inc. (“Neuropathix”) with a new ticker symbol (OTCQB: NPTX).

Read the rest here:
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol

Bagsværd, Denmark, 6 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Here is the original post:
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Continued here:
Virbac : Declaration of the number of shares and voting rights October 2020

Read this article:
Tauriga Sciences, Inc. Experiencing Greater Market Acceptance for its Cannabis (CBD & CBG) Infused Chewing Gum Product Line

- Marked Reductions in Phe Observed at Two Doses -

Continued here:
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman, MD, of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD) to be held November 13-16, 2020.

Read more from the original source:
Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020

Summit Therapeutics Inc.(“Summit” or the “Company”)

See the article here:
Summit Announces Closing of Private Placement of $50 Million

WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020.

More:
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

(Article 223-16 of General Regulation of the French financial markets authority)

More:
Monthly information on share capital and company voting rights

TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”), is pleased to announce that it is proceeding with a consolidation (the “Consolidation”) of its common shares (“Common Shares”) on the basis of 100 pre-Consolidation Common Shares for one (1) post-Consolidation Common Share. The Consolidation was approved by the shareholders of the Company at the Company’s annual general and special meeting of shareholders held on July 31, 2019.

Here is the original post:
Braingrid Limited Announces Share Consolidation

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020.

Excerpt from:
Obalon Announces Third Quarter 2020 Financial Results

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable on a post-reverse stock split basis following the reverse stock split, in the form of contractual rights to receive, (x) one contingent value right (“STING Agonist CVR”) entitling the holder of each such post-split share of common stock to receive, in connection with certain potential future transactions involving Spring Bank’s proprietary STimulator of INterferon Genes (STING) agonist compound designated as SB 11285 occurring on or prior to the STING Agonist CVR Expiration Date (as defined below) that result in certain payments as described below and (y) one contingent value right (“STING Antagonist CVR” and, together with the STING Agonist CVR, the “CVRs”) entitling the holder of each such post-split share of common stock to receive, in connection with the execution of a potential development agreement and certain other transactions involving Spring Bank’s proprietary STING antagonist compound occurring on or prior to the STING Antagonist CVR Expiration Date (as defined below) certain payments as described below.

The rest is here:
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”. The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, and 5 yes, 0 no and 6 uncertain on the question, “Has the Applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology?”. Finally, the Advisory Committee voted 0 yes, 10 no and 1 uncertain on the question, “In light of the understanding provided by the exploratory analyses of Study 301 and Study 302, along with the results of Study 103 and evidence of a pharmacodynamic effect on Alzheimer’s disease pathophysiology, it is reasonable to consider Study 302 as primary evidence of effectiveness of aducanumab for the treatment of Alzheimer’s disease?”

Continued here:
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

CEO Jeff Yapp to assume role of President CEO Jeff Yapp to assume role of President

Excerpt from:
Golden Leaf Holdings Announces Resignation of President Stanley Grissinger

Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials

Read more:
Shockwave IVL Is Superior to Angioplasty in Severely Calcified Peripheral Artery Disease

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a business update.

Read more:
Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update

Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

See the rest here:
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update